Psoriasis is a chronic immune-mediated inflammatory skin disorder, with a prevalence of 2-3% worldwide. Psoriatic lesions affecting scalp, nails, palms, and soles are considered difficult-to-treat and require specific management. When psoriasis involves these areas, it may be considered more severe even if the lesions are not extensive. Adalimumab (Humira®) is a fully human monoclonal antibody against tumor necrosis factor (TNF), administered via subcutaneous injection. It has already been used in the treatment of adults and children with moderate-to-severe chronic plaque psoriasis. In literature, few studies investigated its efficacy in difficult-to-treat areas, hence we conducted an observational prospective study of 24 weeks to assess its role in patients with difficult to treat psoriasis. We found out a significant improvement in nail and scalp psoriasis, whilst palmoplantar and genital psoriasis showed an improvement though not statistically significant. Therefore, adalimumab can be used in difficult-to-treat areas with great results, also allowing an improvement in the quality of life of affected patients, both adults and children. This article is protected by copyright. All rights reserved.

Lanna, C., Zangrilli, A., Bavetta, M., Campione, E., Bianchi, L. (2020). Efficacy and safety of Adalimumab in difficult-to-treat psoriasis. DERMATOLOGIC THERAPY, 33(3) [10.1111/dth.13374].

Efficacy and safety of Adalimumab in difficult-to-treat psoriasis

Zangrilli, Arianna;Campione, Elena;Bianchi, Luca
2020-01-01

Abstract

Psoriasis is a chronic immune-mediated inflammatory skin disorder, with a prevalence of 2-3% worldwide. Psoriatic lesions affecting scalp, nails, palms, and soles are considered difficult-to-treat and require specific management. When psoriasis involves these areas, it may be considered more severe even if the lesions are not extensive. Adalimumab (Humira®) is a fully human monoclonal antibody against tumor necrosis factor (TNF), administered via subcutaneous injection. It has already been used in the treatment of adults and children with moderate-to-severe chronic plaque psoriasis. In literature, few studies investigated its efficacy in difficult-to-treat areas, hence we conducted an observational prospective study of 24 weeks to assess its role in patients with difficult to treat psoriasis. We found out a significant improvement in nail and scalp psoriasis, whilst palmoplantar and genital psoriasis showed an improvement though not statistically significant. Therefore, adalimumab can be used in difficult-to-treat areas with great results, also allowing an improvement in the quality of life of affected patients, both adults and children. This article is protected by copyright. All rights reserved.
2020
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/35 - MALATTIE CUTANEE E VENEREE
English
Lanna, C., Zangrilli, A., Bavetta, M., Campione, E., Bianchi, L. (2020). Efficacy and safety of Adalimumab in difficult-to-treat psoriasis. DERMATOLOGIC THERAPY, 33(3) [10.1111/dth.13374].
Lanna, C; Zangrilli, A; Bavetta, M; Campione, E; Bianchi, L
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
adalimumab, difficult to treat.pdf

solo utenti autorizzati

Licenza: Copyright dell'editore
Dimensione 948.29 kB
Formato Adobe PDF
948.29 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/245066
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 19
  • ???jsp.display-item.citation.isi??? 17
social impact